Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

TEL AVIV, Israel, June 9, 2026 /PRNewswire/ -- – Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the initiation of GMP manufacturing activities at Sheba Medical Center's Advanced...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.